Navigation Links
Labopharm amends debt facility agreement with Hercules
Date:6/25/2009

structuring of the Canadian asset-backed commercial paper, which amount the Company can, under certain conditions, repay at maturity by delivering the notes to the bank.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets, and Australia, among others. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
2. Labopharm Reports Results for First Quarter Fiscal 2009
3. Labopharm announces details for first quarter results conference call and annual meeting
4. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
5. Labopharm to present at Cowen 29th Annual Health Care Conference
6. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
7. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
8. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
9. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
10. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
11. Labopharm Comments on Recent Trading Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 MyRounding, the ... care, has been selected from a group of over ... the 2014 PrIME Digital Health Challenge. The competition will ... another, Tuesday, Sept. 9th at the CSU Denver Atrium ... MyRounding is based in Denver, Colo. The cloud-based, SaaS ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of Medicare ... to announce that it has released a special report ... 2015 Hospital Inpatient Prospective Payment System (IPPS) final rule ... Services. , “Hospitals are facing decreased Medicare reimbursements in ... BESLER’s President and Chief Executive Officer. “We are happy ...
(Date:9/2/2014)... September 02, 2014 “Is there an ... question that millions of people ask. Diagnosing and curing ... patients and their families or treatment partners. The diagnostic ... its distinct similarities to other skin conditions such as: ... bites, eczema, varicella and many others. Scabies is ...
(Date:9/2/2014)... 02, 2014 Michigan’s health care landscape ... Act and the Healthy Michigan Plan. Throughout these changes, ... a trusted funding resource for under-served individuals. Federal and ... or underinsured women between the ages of 50 and ... percent of the federal poverty level. , ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
Breaking Medicine News(10 mins):Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2
... (sildenafil) can improve exercise capacity and functional ability in ... high pressure in the blood vessels that enter the ... report by Reuters, the findings, which appear in The ... study of 278 patients who were randomly selected to ...
... to stress during early life can lead to an ... adolescence.// It therefore, highlights the need for a counseling ... of growth. ,Several studies have established a ... with an increased risk of developing attachment disorders. These ...
... Death Syndrome (SIDS) has found out that nearly all cases ... a male sex hormone. //The levels are considerably higher in ... who have died suddenly from other causes. ,Researchers ... collected from 169 infants who had died of SIDS and ...
... findings were published by chemists at Harvard University, who ... they trigger could hold the key to oncogenesis,// the ... arises when an oncoprotien, a protein known to cause ... development of cancer, 'We present the hypothesis that an ...
... Research Institute have now found out that heart disease ... the thyroid gland.// Aggressive treatment of hypothyroidism and borderline ... diseases to a significant extent. ,The study has ... can be extrapolated to human beings as well. The ...
... of the National Cancer Institute conducted a meta-analysis of ... and the prevalence and associated mortality from colorectal cancer. ... of the Karolinska Institute in Stockholm, and colleagues. The ... at a 30 percent risk of developing colorectal cancer ...
Cached Medicine News:Health News:Teenage Mental Problems Could Be The Result Of Stress During Early Life 2Health News:Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases 2
(Date:9/2/2014)... , Sept. 2, 2014 Redspin, Inc., ... penetration testing services, today released an IT security advisory ... "Today,s healthcare CEOs are presiding over the most ... Daniel W. Berger , Redspin,s President and CEO. ... and their Boards of Directors understand why they need ...
(Date:9/2/2014)... ATLANTA , Sept. 2, 2014  For over a ... show no link between vaccines and autism. But at least ... In a statement , William Thompson ... significant information" linking the MMR vaccine to an increased risk ... of the same data suggests that African American males ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
Breaking Medicine Technology:CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2
... SweetSpot Diabetes Care, Inc. has registered their ... Device Data System (MDDS) with the FDA the Company announced ... Sessions meeting in San Diego, CA. With the ... of data from patient diabetes devices to research tools and ...
... Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," ... that the Group has accumulated 754,791 ordinary shares in its ... the open market between December 2010 and March 2011. As ... the issued share capital of CCBC. CCBC is ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: